Financial Services

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

OSE Immunotherapeutics is taking back a key drug from AbbVie, betting its own cash on a bigger prize. What does this strategic pivot reveal about pharma R&D?

Fresh off its spin-off, the US metals processor is in talks to acquire a German giant, a move that could reshape the global steel industry.

With shareholder approval secured, the HNI-Steelcase merger is set to create a $5.8B powerhouse. But can it deliver on its $120M synergy promise?

As Virginia faces slowing growth, the business community presents a new decade-long economic plan to Governor-elect Spanberger. Can it deliver prosperity?

Up to 60% of disability claims are denied, leaving sick Canadians in financial ruin. We explore the insurer tactics and the fight to reclaim benefits.

The Dot Corp's new division signals a major shift in marketing logistics. Why are companies abandoning siloed vendors for a single source of truth?

A utility is slashing its carbon footprint by 99.9% not with solar or wind, but with an invisible innovation that fixes the grid from the inside out.

Massey Ferguson's award to the World's Oldest Rodeo is more than a gift; it's a strategic look at how heritage brands are powering community impact.

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

An attack on a cat sparks a $10,000 reward, revealing a strategic model where non-profits invest in public safety to protect communities and assets.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

A critical shortage of aircraft mechanics threatens global travel. Now, a trade school's debut on Amazon Prime signals a major shift in valuing skilled careers.

Vermont's WhistlePig isn't just opening a bar in Louisville; it's launching a strategic assault on tradition with an immersive, high-tech whiskey vault.

Hedge fund Balyasny Asset Management reveals a major stake in the Unite-Empiric takeover, signaling a high-stakes arbitrage play amid regulatory scrutiny.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

Abaxx is launching UK wind futures, a critical financial tool to manage renewable energy volatility. Is this the key to de-risking the energy transition?

A new Regina clinic uses high-tech chairs to fight a silent health epidemic, blending innovation with a mission to break the billion-dollar taboo of incontinence.

Immatics just secured $125M. This cash infusion is a major bet on its pioneering PRAME-targeted therapies and a key signal for the future of oncology.

In a routine filing with major implications, Albion Crown VCT directors reinvest dividends, signaling deep faith in the VCT model as tax rules evolve.